-
1
-
-
84855792427
-
Cancer statistics, 2012
-
Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
-
(2012)
CA Cancer J Clin
, vol.62
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
3
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
-
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
4
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
5
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101:13306-13311.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
-
6
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie, the Associazione Italiana Oncologia Toracicathe Associazione Italiana Oncologia Toracica
-
Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246. on behalf of the Spanish Lung Cancer Group in collaboration with the Groupe Français de Pneumo-Cancérologie, the Associazione Italiana Oncologia Toracicathe Associazione Italiana Oncologia Toracica.
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
7
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
-
8
-
-
84867036676
-
Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER)
-
(abstr).
-
Yang PC, Shi Y, Au JS, et al. Molecular epidemiological prospective study of EGFR mutations from Asian patients (pts) with advanced lung adenocarcinoma (PIONEER). Proc Am Soc Clin Oncol 2012, 30(suppl):1534. (abstr).
-
(2012)
Proc Am Soc Clin Oncol
, vol.30
, Issue.SUPPL.
, pp. 1534
-
-
Yang, P.C.1
Shi, Y.2
Au, J.S.3
-
9
-
-
65349161510
-
EGFR testing in lung cancer is ready for prime time
-
Hirsch FR, Bunn PA EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009, 10:432-433.
-
(2009)
Lancet Oncol
, vol.10
, pp. 432-433
-
-
Hirsch, F.R.1
Bunn, P.A.2
-
10
-
-
84859435053
-
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies
-
Tan F, Shen X, Wang D, et al. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 2012, 76:177-182.
-
(2012)
Lung Cancer
, vol.76
, pp. 177-182
-
-
Tan, F.1
Shen, X.2
Wang, D.3
-
11
-
-
79960035905
-
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors
-
Zhao Q, Shentu J, Xu N, et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 2011, 73:195-202.
-
(2011)
Lung Cancer
, vol.73
, pp. 195-202
-
-
Zhao, Q.1
Shentu, J.2
Xu, N.3
-
12
-
-
79960034992
-
Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer
-
Wang H, Zhang L, Wang Y, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 2011, 124:1933-1938.
-
(2011)
Chin Med J (Engl)
, vol.124
, pp. 1933-1938
-
-
Wang, H.1
Zhang, L.2
Wang, Y.3
-
13
-
-
77955836641
-
Pharmocology and clinical evaluation of icotinib hydrochloride
-
(in Chinese).
-
Tan F, Zhang L, Zhao Q, et al. Pharmocology and clinical evaluation of icotinib hydrochloride. Chin J New Drugs 2009, 18:1-4. (in Chinese).
-
(2009)
Chin J New Drugs
, vol.18
, pp. 1-4
-
-
Tan, F.1
Zhang, L.2
Zhao, Q.3
-
14
-
-
80052794272
-
Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
-
Liu D, Jiang J, Zhang L, Tan F, Wang Y, Hu P Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid Commun Mass Spectrom 2011, 25:2131-2140.
-
(2011)
Rapid Commun Mass Spectrom
, vol.25
, pp. 2131-2140
-
-
Liu, D.1
Jiang, J.2
Zhang, L.3
Tan, F.4
Wang, Y.5
Hu, P.6
-
15
-
-
0036569870
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
-
Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20:2240-2250.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2240-2250
-
-
Ranson, M.1
Hammond, L.A.2
Ferry, D.3
-
16
-
-
0029042825
-
Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument
-
Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 1995, 12:199-220.
-
(1995)
Lung Cancer
, vol.12
, pp. 199-220
-
-
Cella, D.F.1
Bonomi, A.E.2
Lloyd, S.R.3
Tulsky, D.S.4
Kaplan, E.5
Bonomi, P.6
-
17
-
-
10744228140
-
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
-
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
-
(2003)
Semin Radiat Oncol
, vol.13
, pp. 176-181
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
-
18
-
-
33645302908
-
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer
-
Park K, Goto K A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin 2006, 22:561-573.
-
(2006)
Curr Med Res Opin
, vol.22
, pp. 561-573
-
-
Park, K.1
Goto, K.2
-
19
-
-
0037472909
-
Design and analysis of non-inferiority mortality trials in oncology
-
Rothmann M, Li N, Chen G, Chi GY, Temple P, Tsou HH Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003, 22:239-264.
-
(2003)
Stat Med
, vol.22
, pp. 239-264
-
-
Rothmann, M.1
Li, N.2
Chen, G.3
Chi, G.Y.4
Temple, P.5
Tsou, H.H.6
-
20
-
-
83555166254
-
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
-
Kim ST, Uhm JE, Lee J, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012, 75:82-88.
-
(2012)
Lung Cancer
, vol.75
, pp. 82-88
-
-
Kim, S.T.1
Uhm, J.E.2
Lee, J.3
-
21
-
-
77953980894
-
Comparison of gefitinib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy
-
Kim ST, Lee J, Kim JH, et al. Comparison of gefitinib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy. Cancer 2010, 116:3025-3033.
-
(2010)
Cancer
, vol.116
, pp. 3025-3033
-
-
Kim, S.T.1
Lee, J.2
Kim, J.H.3
-
22
-
-
79960034992
-
Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer
-
Wang H-P, Zhang L, Wang Y-X, et al. Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 2011, 124:1933-1938.
-
(2011)
Chin Med J (Engl)
, vol.124
, pp. 1933-1938
-
-
Wang, H.-P.1
Zhang, L.2
Wang, Y.-X.3
-
23
-
-
84883051278
-
Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study
-
(abstr).
-
Tan F, Gu A, Zhang Y, et al. Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study. Proc Am Soc Clin Oncol 2013, 31(suppl):19161. (abstr).
-
(2013)
Proc Am Soc Clin Oncol
, vol.31
, Issue.SUPPL.
, pp. 19161
-
-
Tan, F.1
Gu, A.2
Zhang, Y.3
-
24
-
-
76749154617
-
Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy
-
Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16:1307-1314.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1307-1314
-
-
Lee, D.H.1
Park, K.2
Kim, J.H.3
-
25
-
-
33746933434
-
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
-
Jänne PA, Johnson BE Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2006, 12:4416-4420.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4416-4420
-
-
Jänne, P.A.1
Johnson, B.E.2
-
26
-
-
52049090365
-
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR21
-
Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR21. J Clin Oncol 2008, 26:4268-4275.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4268-4275
-
-
Zhu, C.Q.1
da Cunha Santos, G.2
Ding, K.3
-
27
-
-
33750962024
-
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
-
Hirsch FR, Varella-Garcia M, Bunn PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006, 24:5034-5042.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5034-5042
-
-
Hirsch, F.R.1
Varella-Garcia, M.2
Bunn, P.A.3
-
28
-
-
84922687467
-
Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified
-
(in Chinese).
-
Song Z, Yu X, Cai J, et al. Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified. Zhongguo Fei Ai Za Zhi 2013, 16:138-143. (in Chinese).
-
(2013)
Zhongguo Fei Ai Za Zhi
, vol.16
, pp. 138-143
-
-
Song, Z.1
Yu, X.2
Cai, J.3
|